Literature DB >> 2082659

An autopsy case of human T lymphotropic virus type I-associated myelopathy (HAM) with a duration of 28 years.

S Sasaki1, T Komori, S Maruyama, M Takeishi, Y Iwasaki.   

Abstract

An autopsy case of human T lymphotropic virus I-associated myelopathy (HAM) of a duration of 28 years in a 61-year-old man with serological confirmation of HTLV-I infection was reported. The spinal cord was grossly atrophic. There was severe symmetrical degeneration of the lateral funiculi, particularly of the bilateral pyramidal tracts, involving all levels of the spinal cord, but anterior horn cells were relatively well preserved. In the most severely damaged middle and lower thoracic segments, the white matter degeneration also involved the anterior funiculi. In the degenerated white matter, both the myelin and axons were equally lost and had been replaced by glial scars. Marked adventitial fibrosis was commonly seen in small parenchymal vessels in both the white and gray matter. Although there was no evidence of inflammation in the spinal cord, mild lymphocytic infiltration was occasionally observed in the subarachnoid and perivascular spaces in the brain stem, cerebellum and cerebrum. This case was considered as a burnt-out case of HAM.

Entities:  

Mesh:

Year:  1990        PMID: 2082659     DOI: 10.1007/BF00334512

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  20 in total

1.  CLINICAL AND PATHOLOGICAL OBSERVATIONS ON JAMAICAN NEUROPATHY; A REPORT ON 206 CASES.

Authors:  R D MONTGOMERY; E K CRUICKSHANK; W B ROBERTSON; W H MCMENEMEY
Journal:  Brain       Date:  1964-09       Impact factor: 13.501

2.  Increased replication of HTLV-I in HTLV-I-associated myelopathy.

Authors:  M Yoshida; M Osame; H Kawai; M Toita; N Kuwasaki; Y Nishida; Y Hiraki; K Takahashi; K Nomura; S Sonoda
Journal:  Ann Neurol       Date:  1989-09       Impact factor: 10.422

3.  Identification of the normal microglial population in human and rodent nervous tissue using lectin-histochemistry.

Authors:  H Suzuki; H Franz; T Yamamoto; Y Iwasaki; H Konno
Journal:  Neuropathol Appl Neurobiol       Date:  1988 May-Jun       Impact factor: 8.090

4.  Identity of HTLV-I-associated tropical spastic paraparesis and HTLV-I-associated myelopathy.

Authors:  G C Román; M Osame
Journal:  Lancet       Date:  1988-03-19       Impact factor: 79.321

5.  HTLV-I infection of cerebrospinal fluid T cells from patients with chronic neurologic disease.

Authors:  E DeFreitas; Z Wroblewska; G Maul; W Sheremata; P Ferrante; E Lavi; M Harper; F di Marzo-Veronese; H Koprowski
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

6.  Necropsy findings in HTLV-I associated myelopathy.

Authors:  S Akizuki; O Nakazato; Y Higuchi; K Tanabe; M Setoguchi; S Yoshida; Y Miyazaki; S Yamamoto; S Sudou; K Sannomiya
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

7.  Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells.

Authors:  M Osame; M Matsumoto; K Usuku; S Izumo; N Ijichi; H Amitani; M Tara; A Igata
Journal:  Ann Neurol       Date:  1987-02       Impact factor: 10.422

8.  Spastic paraplegia-paraparesis. A reappraisal.

Authors:  J Y Ungar-Sargon; R E Lovelace; J C Brust
Journal:  J Neurol Sci       Date:  1980-04       Impact factor: 3.181

9.  Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom.

Authors:  J K Cruickshank; P Rudge; A G Dalgleish; M Newton; B N McLean; R O Barnard; B E Kendall; D H Miller
Journal:  Brain       Date:  1989-08       Impact factor: 13.501

10.  Detection of human T-cell lymphoma/leukemia virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy.

Authors:  S Bhagavati; G Ehrlich; R W Kula; S Kwok; J Sninsky; V Udani; B J Poiesz
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

View more
  2 in total

1.  Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.

Authors:  H H Biswas; J W Engstrom; Z Kaidarova; G Garratty; J W Gibble; B H Newman; J W Smith; A Ziman; J L Fridey; R A Sacher; E L Murphy
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

2.  Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.

Authors:  Massanobu Takatani; Myuki Esashika Crispim; Nelson Fraiji; Mariane Martins Araujo Stefani; Dagmar Kiesslich
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.